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ABSTRACT
Objective: The aim of the study was to evaluate determinants for the prognosis of asthma in a
population-based cohort of young adults.
Design: The study was a nine-year clinical follow up of 239 asthmatic subjects from an enriched
population-based sample of 1,191 young adults, aged 20–44 years, who participated in an
interviewer-administered questionnaire and clinical examination at baseline in 2003–2006. From
the interview, an asthma score was generated as the simple sum of affirmative answers to five
main asthma-like symptoms in order to analyse symptoms of asthma as a continuum. The clinical
examination comprised spirometry, bronchial challenge or bronchodilation, and skin prick test.
Results: Among the 239 individuals with asthma at baseline 164 (69%) had persistent asthma at
follow up, while 68 (28%) achieved remission of asthma and seven (3%) were diagnosed with COPD
solely. Determinants for persistent asthma were use of medication for breathing within the last
12 months: Short-acting beta-adrenoceptor agonists (SABA) only (OR 3.39; 95%CI: 1.47–7.82) and
inhaled corticosteroids (ICS) and/or long-acting beta-adrenoceptor agonists (LABA) (8.95; 3.87–
20.69). Stratified by age of onset determinants for persistence in individuals with early-onset asthma
(age less than 16 years) were FEV₁ below predicted (7.12; 1.61–31.50), asthma score at baseline
(2.06; 1.15–3.68) and use of ICS and/or LABA within 12 months (9.87; 1.95–49.98). In individuals with
late-onset asthma the determinant was use of ICS and/or LABA within 12 months (6.84; 2.09–22.37).
Conclusions: Pulmonary function below predicted, severity of disease expressed by asthma score
and use of ICS and/or LABA were all determinants for persistent early-onset asthma, whereas only
use of ICS and/or LABA was a determinant in late-onset asthma. A high asthma score indicated
insufficient disease control in a substantial proportion of these young adults.
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Introduction
Asthma is a common complex respiratory disorder
with various overlapping phenotypes [1,2]. Common
features include fluctuating respiratory symptoms asso-
ciated with variable airflow limitation and bronchial
hyperresponsiveness (BHR) due to inflammation of
the airways. The age of asthma onset is an important
factor for dividing the phenotypes and a major deter-
minant of the prognosis [3–5], but the prognosis for
adult-onset asthma is only sparsely documented [6]. In
a prospective study of individuals with adult-onset
asthma higher age, higher body mass index (BMI)
and low lung function were associated with greater
asthma severity, while non-sensitisation and a normal
lung function were predictors for remission [7]. A
review has shown that adult-onset asthma has a worse
prognosis and a lower response to standard asthma
treatment than childhood-onset asthma [8]. In a 12-
year follow-up study of adult-onset asthma elevated
BMI at baseline, smoking and current allergic or
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persistent rhinitis predicted uncontrolled asthma, and
elevated blood eosinophils and good lung function
(FEV1) at baseline protected from uncontrolled asthma
[9]. Remission rates vary widely due to varying defini-
tions of asthma and observation time but generally
early-onset asthma has a substantially higher remission
rate than late-onset asthma [10].
Despite reported remission of asthma the disease is
usually considered as a treatable, but not curable disease
once present [11]. The understanding of determinants
that affect the course of diagnosed asthma, e.g. avoidance
of environmental or occupational exposures [12], is
therefore important for tertiary prevention, since asthma
persistence is associated with frequent and severe symp-
toms with development of impaired lung function [13].
In a recent publication, we have reported risk factors
for incident asthma in a cohort of young adults [14].
The aim of the present study was to evaluate determi-
nants for the prognosis of asthma in the same cohort.
Methods
The present study was a 9-year clinical follow up of 239
individuals with asthma from an enriched population-
based sample of 1,191 young adults who participated in
an interviewer-administered questionnaire and clinical
examination at baseline in 2003–2006, the RAV-study
(Risk Factors for Asthma in Adults). The protocol was
based on the European Community Respiratory Health
Survey II (ECRHS II) [15] and the baseline study has been
reported elsewhere [16]. In brief, the baseline study popu-
lation comprised a random sample of 10,000 individuals,
aged 20–44 years and standardised by sex and age.
Among 7,271 (73%) individuals who answered a screen-
ing questionnaire (Phase 1), a random sample corre-
sponding to 20% of the study population plus a
complementary symptom group of individuals reporting
respiratory symptoms were invited to an interview and
clinical examination (Phase 2). Of 1,191 subjects who
participated in the clinical examination at baseline 424
had asthma. A total of 742 (62%) individuals were re-
examined at follow up in 2012–2014 leaving 239 subjects
with asthma at baseline for further analysis.
Ethical approval for the study was obtained by The
Regional Scientific Ethical Committee for Southern
Denmark and written informed consent was obtained
from all participants.
Interview
The interview at baseline and follow up was a slightly
modified electronic ECRHS main questionnaire per-
formed in connection to the clinical examination by
skilled interviewers trained in standardised interview
technique. The interview comprised items on asthma
history, asthma-like symptoms, medication, smoking
habits, education and occupation.
Clinical examination
The clinical examination at baseline comprised a spiro-
metry using a MicroLoop Spirometer (Micro Medical,
Rochester, UK) and a skin prick test (SPT). The spiro-
metry was followed by a methacholine challenge test
using a Mefar MB3 dosimeter (Mefar, Bovezzo, Italy)
or bronchodilation by inhalation of Terbutalin, 1.5 mg
if forced expiratory volume in 1 s (FEV₁) was <70% of
predicted or <1.5 l. The SPT comprised a panel of 13
commercially available inhalation allergens from ALK-
Abelló, Gentofte, Denmark.
The spirometry at follow up was carried out by using
an EasyOne Spirometer (ndd Medical Technologies,
Andover, MA, USA) followed by bronchodilation by
inhalation of Salbutamol, 0.2 mg from spacer
(AeroChamber Plus Flow-Vu) following the ERS guide-
lines for standardisation of spirometry [17].
Diagnoses
Asthma at baseline was defined by an affirmative
answer to the question ‘Have you ever had asthma’?
combined with asthma-like symptoms, use of medica-
tion for breathing within the last 12 months or airflow
obstruction according to a modified definition used by
de Marco et al. in a recent study [18] (Table S1).
Obstruction was defined according to the lower limit
of normal (LLN) [19] i.e. the 5th percentile of FEV₁/
FVC distribution corresponding to a z-score <−1.64. At
baseline, the maximum values of FEV₁ and FVC were
applied without reversibility testing since methacholine
challenge test was performed. At follow up, the max-
imum value was the best of either the pre-bronchodi-
lator (pre-BD) or post-bronchodilator (post-BD) value.
COPD was defined according to criteria of LLN com-
bined with symptoms consistent with COPD, modified
from de Marco et al. [18] (Table S1). Transient airflow
obstruction was defined by obstruction at baseline but
no obstruction at follow up, while fixed obstruction
was defined by having post-BD obstruction at follow
up. Incident cases of asthma and COPD during the
follow-up period were identified by applying the defi-
nitions used at baseline, although slightly modified
since BHR was not measured at follow up (Table S1).
Asthma-COPD overlap syndrome (ACOS) was defined
when criteria for both asthma and for COPD were met.
Early-onset asthma was defined when age of first attack
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of asthma was less than 16 years and late-onset when
16 years or more. Remission of asthma was defined by
not fulfilling the criteria for asthma at follow up.
Determinants
BHR at baseline was defined as a 20% fall or more in
FEV₁ after a dose of 1 mg methacholine or less. The
bronchodilation was positive with an increase in FEV₁
of ≥12% and ≥200 ml. FEV₁ below predicted was defined
by FEV₁<100% predicted corresponding to a z-score<0
[19]. Atopy was defined by one or more positive SPT
(mean wheal diameter ≥3 mm). The type of medication
used for breathing within the last 12 months was
recorded and categorised into three levels: (1) no medica-
tion, (2) only short-acting beta-adrenoceptor agonists
(SABA), and (3) inhalation corticosteroid (ICS) and/or
long-acting beta-adrenoceptor agonists (LABA). The
applied five-item asthma score was developed by
Pekkanen, Sunyer et al. [20,21] and consisted of the
simple sum of affirmative answers to five main asthma-
like symptoms ranging from zero to five, not including
questions regarding asthma attacks or asthma medica-
tion, in order to grade symptoms of asthma as a conti-
nuum (Table S2). Current smoking at baseline was
defined in individuals, who reported smoking for at
least one year and were still smoking. Occupation at
baseline, reported as the last held job, was coded accord-
ing to the International Standard Classification of
Occupations from 1988 (ISCO88) and classified in high-
and low-risk jobs for asthma and COPD, respectively
using job grouping tools formerly applied in the ECRHS
[22]. Furthermore, participants were categorised in white
and blue collar workers by using ISCO88-code <6000 and
≥6000, respectively.
Statistical analyses
Univariate and multivariate analyses were conducted by
logistic regression models calculating odds ratios (OR)
with 95% confidence intervals (CI) for the association
between the dependent outcome (asthma or COPD) and
the independent determinants with mutual adjustment
for potential confounders. Univariate analyses were per-
formed on a comprehensive set of potential determi-
nants. For the multivariate analyses, a reduced set of
determinants was selected based on clinical relevance
and specific interest i.e. sex, FEV₁ below pred., BHR,
ACOS, asthma score, medication for breathing, current
smoking, and high-risk occupation. The analyses of
asthma score as an outcome were performed using the
score as a continuous variable. Supplementary we ana-
lysed the asthma score as a categorical variable.
Asthma score was analysed by ordered logistic
regression calculating ORs. FEV₁ at baseline and at
follow up was analysed by linear regression. Results
were considered statistically significant at p < 0.05.
Analyses were carried out using Stata, version 13.1
(StataCorp, College Station, Texas, USA).
Results
Among the 1,191 participants of the baseline study, 449
individuals were lost to follow up. Withdrawal analyses
showed that the proportion of cases of asthma at baseline
did not differ between participants and non-responders
(32.2% vs. 27.8%, p = 0.120). Compared to non-respon-
ders a larger proportion of the participants were older
than 35 years old (53.6% vs. 41.4%; p = 0.000) and
reported nasal allergy (42.1% vs. 32.3%; p = 0.001)
whereas a smaller proportion were female (53.6% vs.
60.6%; p = 0.022) and current smoker (27.0% vs. 33.0%;
p = 0.030). Participants and non-responders did not differ
significantly concerning the other variables analysed.
Among the 239 individuals with asthma at baseline,
193 (81%) had asthma solely while 46 (19%) had ACOS.
During follow up, 68 (28%) individuals were in remis-
sion and seven (3%) were diagnosed with COPD with-
out having asthma. This left 164 (69%) individuals with
persistent asthma at follow up of whom 136 (83%) had
asthma solely and 28 (17%) had ACOS. Individuals with
ACOS at baseline had a lower remission rate than those
with asthma solely (9% vs. 33%; p = 0.009).
Characteristics of the study population and associa-
tions with determinants at baseline by diagnosis at
follow up are shown in Table 1. There was an almost
equal distribution of individuals with early- and late-
onset asthma. The risk of persistent asthma increased
with increasing asthma score at baseline, both when
the score was analysed as a continuous variable and
when analysed as a categorical variable (data not
shown). Current smoking at baseline was associated
with a reduced risk of persistent asthma at follow up.
Of 68 individuals who were smoking at baseline, 27
(40%) ceased smoking during follow up of whom 15
had persistent asthma and 12 were in remission at
follow up (p = 0.88).
Figure 1 shows that the average five-item asthma
score decreased from baseline to follow up (mean 2.00
vs. 1.47, p < 0.001), which was also the case for the group
of individuals with persistent asthma (mean 2.25 vs. 1.86,
p = 0.004). The percentage of individuals reporting use of
medication for breathing increased with increasing
asthma score, but there was no change in the proportion
of use of medication from baseline to follow up.
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Table 1. Characteristics of the asthmatic individuals and unadjusted associations of baseline determinants (OR) with persistent
asthma and COPD at follow up.
Diagnosis at follow up
Asthma at baseline (n = 239) Persistent asthma (n = 164) COPD (n = 35)
Determinants, baseline n (%) n (%) OR (95%CI) n (%) OR (95%CI)
Sex, female 150 (62.8%) 99 (60.4%) 0.72 (0.38–1.32) 22 (62.9%) 1.00 (0.45–2.31)
Age ≥35 years 122 (51.1%) 80 (48.8%) 0.75 (0.42–1.34) 22 (62.9%) 1.76 (0.80–4.01)
Age of onset ≥16 yearsa 119 (55.6%) 81 (52.3%) 0.60 (0.31–1.17) 15 (48.4%) 0.71 (0.31–1.64)
Bronchial hyperresponsivenessb 95 (39.8%) 65 (39.6%) 1.11 (0.60–2.07) 14 (40.0%) 1.81 (0.71–4.81)
Atopy 146 (61.1%) 104 (63.4%) 1.36 (0.75–2.46) 17 (48.6%) 0.55 (0.25–1.21)
FEV₁ below pred 191 (79.9%) 139 (84.8%) 2.46 (1.21–4.95) 33 (94.3%) 4.80 (1.15–42.65)
ACOS 46 (19.3%) 39 (23.8%) 3.03 (1.25–8.43) 19 (54.3%) 7.78 (3.31–18.23)
Medication, 12 mth
SABA only 63 (26.4%) 48 (29.3%) 5.06 (2.43–10.54) 8 (22.9%) 1.15 (0.42–3.17)
ICS and/or LABA 96 (40.2%) 85 (51.8%) 12.21 (5.64–26.45) 18 (51.4%) 1.82 (0.77–4.31)
Asthma Scorec 1.48 (1.20–1.82) 1.16 (0.91–1.48)
BMI >30 kggm−2d 46 (19.3%) 31 (19.0%) 0.94 (0.45–2.02) 5 (14.3%) 0.66 (0.19–1.87)
Nasal allergy 168 (70.3%) 122 (74.4%) 1.83 (0.98–3.41) 22 (62.9%) 0.67 (0.30–1.56)
Parental asthma 92 (38.5%) 67 (40.9%) 1.38 (0.75–2.57) 13 (37.1%) 0.93 (0.41–2.07)
Current smoking 68 (28.5%) 37 (22.6%) 0.41 (0.22–0.78) 14 (40.0%) 1.85 (0.81–4.13)
High-risk occupation (asthma)e 119 (50.4%) 81 (50.0%) 0.95 (0.53–1.70) 15 (42.9%) 0.70 (0.31–1.53)
High-risk occupation (COPD)f 126 (53.4%) 85 (52.5%) 0.89 (0.49–1.60) 16 (45.7%) 0.70 (0.32–1.52)
White collar workg 153 (64.6%) 103 (63.2%) 0.70 (0.32–1.47) 22 (62.9%) 0.76 (0.31–1.93)
Blue collar workg 55 (23.2%) 41 (25.2%) 1.42 (0.68–3.09) 10 (28.6%) 1.32 (0.52–3.18)
Respiratory infection <5 years of age 30 (12.6%) 23 (14.0%) 1.58 (0.62–4.58) 8 (22.9%) 2.45 (0.85–6.43)
Mould inside the home 85 (35.6%) 57 (34.8%) 0.89 (0.49–1.65) 15 (42.9%) 1.44 (0.64–3.15)
Bold values denote significant associations (p < 0.05).
an = 214; 25 participants missing in variable ‘age at onset’.
bn = 210; 29 missing i.e. did not receive methacholine challenge test
cAsthma score as a continuous variable.
dn = 238; 1 participant missing in variable BMI.
en = 236; 3 participants missing in variable ‘high-risk occupation (asthma)’.
fn = 236; 3 participants missing in variable ‘high-risk occupation (COPD)’.
gn = 208; 2 participants missing, 29 unclassifiable.
The table shows odds ratios (OR) with 95% confidence intervals (95% CI).
Figure 1. The distribution of asthma score at baseline (green) and follow up (red) and the percentage of individuals in each group
reporting use of medication for breathing within the last 12 months by asthma score at baseline and follow up, respectively.
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All of the five questions defining asthma score predicted
risk of persistent asthma in unadjusted analyses (Table S2),
but only an affirmative answer to the question ‘shortness of
breath while wheezing or whistling in the last 12 months’
revealed an increased risk of persistent asthma in the
mutually adjusted analysis. None of the questions showed
significant association to COPD at follow up.
In the adjusted analyses, determinants associated with
persistence of asthma at follow up (Table 2) were use of
SABA and use of ICS and/or LABA, whereas current
smoking showed a reduced risk. Age of onset of asthma
showed heterogeneity. In individuals with early-onset
asthma FEV₁ below predicted, asthma score and use of
ICS and/or LABA at baseline determined an increased
risk, while use of ICS and/or LABA was the only deter-
minant of persistent late-onset asthma.
The adjusted analyses of the association between
baseline determinants and asthma score at follow up
and FEV₁ at baseline and follow up are shown in
Table 3. At follow up, all determinants except current
smoking were positively associated with asthma score
although not significantly, which was independent of
the diagnostic criteria applied.
FEV₁ decreased in average 196 ml from baseline to
follow up corresponding to 21.3 ml/year, which is
19.4 ml/year in individuals with early-onset asthma
and 22.5 ml/year in late-onset (data not shown). At
baseline, the presence of ACOS was associated with a
reduced FEV₁. At follow up, only medication with
SABA predicted a lower decline in FEV₁ compared to
those without medication. If the initial FEV1 at follow
up was analysed the average annual fall was 37.6 ml/
year with no difference related to age at onset.
Discussion
In the present population-based cohort study of
young adults, a considerable remission rate was
found and during the 9-year follow up the average
asthma score based on frequency of asthma-like
symptoms declined even in individuals with persistent
asthma. Using medication for breathing within
12 months before baseline predicted overall persistent
asthma nine years later. Age at onset of asthma
showed different determinants of persistent asthma
as FEV₁ below predicted, asthma score and use of
ICS and/or LABA were all determinants in individuals
with early-onset asthma, while use of ICS and/or
LABA was the only determinant in individuals with
late-onset asthma. However, there was indication of
insufficient asthma control in the present cohort since
a considerable fraction of individuals with persistent
asthma had several symptoms at follow up. Ta
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The different baseline determinants associated with an
increased risk of persistent asthma in the two groups
described by the age of onset may reflect characteristics
of two distinct phenotypes. We demonstrated an impact
of FEV₁ below predicted on the risk of persistent asthma
in individuals with early-onset asthma, which is in accor-
dance with a recent study in which the impact on lung
function of early-onset asthma was considerably greater
than for late-onset asthma [23].Wewere not able to show
an impact of atopy on the persistence of asthma, but in a
recent review comparing studies on early- and late-onset
of current asthma, the findings showed that adults with
early-onset disease were more likely to be atopic and had
a higher frequency of asthma attacks, whereas adults with
late-onset disease were more likely to be female and had
greater degrees of fixed airflow obstruction [24].
The use of medication at baseline was a determinant
for persistence of disease in the present study. The use
of ICS and/or LABA was a stronger determinant than
the use of SABA only. This may reflect more severe
disease when using long-term controllers than short-
term relievers. The strongest association was seen in
individuals with early-onset asthma which may like-
wise indicate more severe disease. Use of asthma med-
ication in early- and late-onset asthma has been
reported, but details vary between studies [24].
In the present study, the applied asthma score demon-
strated its usability since increasing asthma score at base-
line predicted an increased risk of persistent asthma in
individuals with early-onset asthma, while there was no
increased risk of later COPD. A substantial proportion of
individuals had asthma score equal to zero at baseline
(18.8%) and at follow up (36.8%). This may be due to
mild cases diagnosed by the diagnostic criteria or due to
individuals who remitted during follow up. However,
results concerning asthma score in the adjusted models
must be interpreted with caution since the five questions
comprising the asthma score are part of the diagnostic
criteria, which additionally includes supplementary ques-
tions on asthma attacks and medication as well as BHR
and airway obstruction. When the asthma score was
analysed independently of the diagnostic criteria
(Table 3), a positive association was still demonstrated
in the majority of determinants analysed thus supporting
the applicability of the score.
The decreased asthma score during follow up may
reflect the individuals who achieved remission during
follow up as well as regression towards the mean since
all individuals had asthma at baseline. Alternatively, it
may imply some effect of asthma treatment during
follow up or that the asthma score actually does not
fully cover the spectrum of symptoms. However, at
follow up a substantial part of individuals who reported
use of medication for breathing had a considerable
number of symptoms expressed by the asthma score
indicating partly controlled or uncontrolled asthma.
This emphasises the need for further medication even
though some may have treatment resistant asthma.
We showed no overall change in use of medication
for breathing from baseline to follow up. A considerable
proportion of individuals were not medicated at all
regardless of symptoms and even in individuals with
asthma scores on 4–5 more than 10% were not currently
medicated and only about half used controller medica-
tion indicating a need for treatment even though poor
adherence may also play a role [25]. These findings are
in accordance with previous studies showing that insuf-
ficient symptom control of asthma remains frequent
among individuals with asthma [26,27].
The lung function data showed an overall decline in
FEV₁ of 21.3 ml per year in individuals with current
asthma at baseline. This is not different from predicted
Table 3. Association between baseline determinants and asthma score at follow up (OR per step increase), FEV₁ at baseline and FEV₁
at follow up (coeff.).
Asthma score at follow up FEV₁ at baseline (liter) FEV₁ at follow up (liter)
Determinants, baseline OR (95%CI) Coefficient (95%CI) Coefficient (95%CI)
Sex, female 1.07 (0.65–1.74) −1.006 (−1.144−0.868) 0.050 (−0.050–0.151)
FEV₁ – – 1.026 (0.958–1.095)
FEV₁ below pred. 1.44 (0.78–2.66) – –
Bronchial hyperresponsiveness 1.37 (0.84–2.23) −0.014 (−0.149–0.121) −0.004 (−0.075–0.068)
ACOS 1.66 (0.88–3.11) −0.398 (−0.576−0.221) 0.025 (−0.072–0.123)
Asthma Score per step increase 1.60 (1.34–1.91) 0.007 (−0.042–0.055) −0.001 (−0.027–0.024)
Medication, 12 mth
SABA only 1.50 (0.77–2.94) 0.046 (−0.138–0.231) 0.099 (0.002–0.196)
ICS and/or LABA 1.14 (0.63–2.08) 0.005 (−0.162–0.172) 0.029 (−0.059–0.117)
Current smoking 0.89 (0.51–1.57) −0.141 (−0.295–0.014) 0.020 (−0.062–0.102)
High-risk occupation (asthma)a 1.16 (0.31–4.28) 0.133 (−0.266–0.531) 0.076 (−0.134–0.285)
High-risk occupation (COPD) b 1.26 (0.34–4.68) −0.047 (−0.444–0.350) −0.042 (−0.250–0.167)
Bold values denote significant associations (p < 0.05).
an = 236; 3 participants had missing in variable ‘high-risk occupation (asthma)’.
bn = 236; 3 participants had missing in variable ‘high-risk occupation (COPD)’.
Regarding FEV₁ negative numbers report larger decrease. The table shows odds ratios (OR) and regression coefficients with 95% confidence intervals (95% CI).
6 L. K. TRAULSEN ET AL.
in non-asthmatic subjects but the results may be evalu-
ated with caution since pre-BD FEV₁was used at baseline
and post-BD at follow up which may tend to underesti-
mate the value although best FEV₁ was used at both
occasions. Analyses using pre-BD values showed larger
decline per year, but did not influence on the role of the
other determinants in the multivariate analyses. Previous
studies have suggested accelerated lung function declines
in asthma [28,29] and in a review of adult-onset asthma
decline in FEV₁ varied between 25 and 95ml per year [6].
Still, recent studies have found decline in FEV₁ in asth-
matics of 25.3 [18] and 25.6 ml [30] per year, respectively.
When adjusted for FEV₁ at baseline, determinants for
change in lung function during follow up showed a
smaller decrease of 50 ml (corresponding to 5.5 ml per
year) in females than inmales which may reflect the more
than one liter lower FEV₁ in females overall compared to
males at baseline. Equal to this, individuals with ACOS
and individuals who were current smokers showed a
reduced lung function of nearly 0.40 and 0.14 l, respec-
tively, at baseline in comparison with their references i.e.
healthy individuals and non-smokers, respectively. These
determinants may have played a role even before baseline
which may be the reason for the lowered decline in lung
function than their references during follow up.
The issue of asthma and smoking remains contro-
versial. In the present study, smoking was associated
with a reduced risk of persistent asthma, which could
be due to a ‘healthy smoker effect’, i.e. individuals with
asthma at baseline had quit smoking earlier or had
never started smoking due to airway symptoms since
no difference between persistent asthma and remission
was found among the individuals who ceased smoking
during follow up. Previous studies have suggested that
smoking may have a negative effect on longitudinal
changes in lung function in individuals with asthma
[31]. A recent large study on asthma in the general
population aged 20–100 years showed that smoking
was the main explanation of poor prognosis and
comorbidities in individuals with asthma during
4.5 years of follow up [32].
We were not able to confirm the findings in other
studies showing poor prognosis of asthma in indivi-
duals with high-risk occupation [33]. The analyses
showed no significant correlation between high-risk
occupation and persisting asthma, which could be
due to the young age of the study population, the
relatively short duration of follow up or a ’healthy
worker effect’, i.e. that subjects with asthma before
baseline had chosen an occupation that would not
provoke or exacerbate their airway symptoms.
We found that 29% of the individuals with current
asthma at baseline achieved remission during follow
up, which is slightly higher than the recent comparable
longitudinal study using similar follow-up period and
diagnostic criteria in which the remission of current
adult asthma was 22.2% [18]. Nearly the same range of
remission was reported in a study of individuals with
self-reported current asthma sampled from the Italian
population in which 30% recovered from their asthma
after about 10 years [34]. The prevalence of remission
of asthma in adults has been reported in the range
from 5 to 40%, and usually limited to individuals
with mild disease [10,35,36]. However, remission rates
can be difficult to compare since there is no golden
standard to define remission [6].
Individuals with ACOS at baseline had higher – how-
ever not significant – risk of persistent asthma than
individuals with asthma solely. This is in line with a
recent study of young adults in the same age range [18]
suggesting that ACOS may represent a phenotype with
severe asthma, which progresses to fixed airflow obstruc-
tion, possibly due to structural changes in the airways.
This is supported by the observation that the determi-
nants for persistent asthma, i.e. use of medication were
not associated to COPD at follow up. A recent study of
different phenotypes of chronic airway diseases in the
general population confirmed the poor prognosis of indi-
viduals with ACOS, especially in a subgroup with late-
onset asthma defined by current self-reported asthma
with onset after 40 years of age [30].
The present study is population-based which con-
stitutes a strength when evaluating determinants for
prognosis of asthma in the general population. The
longitudinal study design and the use of validated and
internationally applied questionnaires and clinical
examinations including measurements of pulmonary
function of all participants are further strengths
[37,38]. By use of multivariate logistic regression mod-
els in the analysis, we believe to have controlled for
confounding factors potentially able to have an impact
on the outcome, i.e. persistent asthma.
Although the study was population based, a risk of
selection bias exists since asthmatic individuals with
more severe airway symptoms may be more prone to
participate than individuals with minor symptoms.
Misclassification of disease status may have occurred
due to the choice of diagnostic criteria. By use of self-
reported information, individuals in remission who
reported ever asthma at baseline may have been mild
cases without symptoms at follow up. Furthermore, we
may have overestimated the number of cases of COPD
by using the LLN by the 5th percentile of FEV₁/FVC
corresponding to z-score <−1.64, and the relatively low
dose of beta-agonist chosen due to the study setting in
a general population [39]. The use of two different
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kinds of spirometers, one with a turbine (MicroLoop)
at baseline and one with ultra-sound transit time mea-
surement (ndd EasyOne) at follow up may have
affected the lung function data although calibration
check was performed daily on both spirometers to
minimise this bias. Furthermore, definitions of the
age limit between early- and late-onset asthma vary
widely in the literature [6,8,24]. However, the applied
criteria for asthma and COPD are in line with recent
research [18]. The cut-off at 16 years was chosen at
baseline in order to evaluate risk of occupational fac-
tors in a relevant group.
Limitations of the study include the size of the study
population with a limited number of individuals having
asthma leading to low power of the analyses even
though we used an enriched sample, and further sub-
group analyses to evaluate the impact of potential effect
modification were not performed.
Conclusion
The present study showed that determinants for persis-
tent asthma in young adults differed according to age at
onset of disease. Pulmonary function below predicted,
increased asthma score and use of medication for breath-
ing within 12 months before baseline determined persis-
tence of asthma in individuals with early-onset disease,
while use of medication was the only determinant for
persistence in individuals with late-onset asthma. Use of
controller medication for breathing showed stronger
association with persistent asthma than only use of relie-
ver medication in both groups.
Evaluation of asthma score and use of asthma medica-
tion indicated insufficiently treated asthma underlining
the importance of regular monitoring of symptoms, pul-
monary function, and treatment of adult asthma.
Furthermore, in comparison with asthma, the diagnosis
of ACOS at baseline was associated with an increased yet
not significant risk of persisting asthma at follow up,
which in line with other studies indicates that ACOS
represents a phenotype of severe asthma.
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